Chimeric antigen receptor (CAR) T cells therapy has emerged as a significant breakthrough in adoptive immunotherapy for hematological malignancies with FDA approval. However. the application of CAR-T cell therapy in solid tumors remains challenging. mostly due to lack of suitable CAR-T target antigens. https://poolsproductscanadas.shop/product-category/kafko-equator-parts/